Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Multicentric Observational Trial Of Pegylated Liposomal Doxorubicin For Metastatic Breast Cancer

J. Huober, W. Fett, A. Nusch, M. Neise, M. Schmidt, A. Wischnik, Steffen Gerhardt, T. Goehler, H. Lueck, A. Rost
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BackgroundPegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD in patients treated during routine clinical practice.MethodsEligible patients had metastatic breast cancer and were treated with PLD according to the dose and schedule determined by their physician as part of routine practice. The primary objectives were to analyze the efficacy and toxicity of PLD therapy.Results125 patients were assessable. Median age was 62 years, 78% had performance status 0-1, and 60% had estrogen-receptor-positive disease. PLD treatment was second- or third-line in 69% of patients. Prior anthracyclines (adjuvant or metastatic) had been used in 56% of patients. The majority of patients (79%) received PLD every 4 weeks at a median dose of 40 mg/m2. Overall response rate was 43% in all patients and 34% in those previously treated with anthracyclines. The most common grade 3/4 adverse events were skin toxicity/hand-foot syndrome (6%), and leukopenia (3%).ConclusionsThis observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials.
This paper references
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
10.1093/annonc/mdp115
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
F. Cardoso (2009)
10.1586/14737140.8.3.331
Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer
A. Minisini (2008)
Schering-Plough Corporation
(2007)
CAELYX [package insert]: Kenilworth, NJ: Schering-Plough Corporation
(2007)
Brommels M: Organizational role stress among medical school faculty members in Iran: dealing with role conflict. BMC Med Educ 2007, 7:14. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com
10.1159/000093005
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
S. Al-Batran (2006)
10.1159/000112730
Use of Systemic Antineoplastic Drug Therapy after Regulatory Agency Approval
M. Markman (2007)
10.1159/000127434
Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’
C. Jackisch (2008)
Pegylated liposomal doxorubicin in elderly patients with metastatic breast can
M Markman (2008)
10.1023/A:1008370930599
Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group.
M. O'Brien (1999)
10.1159/000080363
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
B. Mlineritsch (2004)
10.1016/J.CRITREVONC.2006.07.008
A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer.
L. Biganzoli (2007)
10.1016/j.ctrv.2008.01.008
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
S. Verma (2008)
10.1159/000127411
Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients
J. Kurtz (2007)
10.1093/ANNONC/MDL477
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
D. Lorusso (2007)
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC10993)
RE Coleman (2006)
10.1097/CAD.0b013e3282f14a00
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
M. O'Brien (2008)
Phase II trial of pegylated liposomal doxorubicincyclophosphamide in combination as first-line chemotherapy in older metastatic breast cancer patients
JE Kurtz (2007)
What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及
青儀 健二郎 (2006)
10.1634/THEONCOLOGIST.10-3-205
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
P. Rose (2005)
10.1016/J.EJCA.2005.12.011
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
Ann Oncol
(2008)
10.1006/GYNO.2001.6272
Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
P. Rose (2001)
10.1159/000112731
Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study
M. Salzberg (2007)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
Pre-publication history
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (2005)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1038/sj.bjc.6603158
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)



This paper is referenced by
10.1016/J.EJOGRB.2011.06.020
The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women.
L. Santos (2011)
10.2459/JCM.0000000000000382
Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies
C. Cadeddu (2016)
Improvement of biodistribution with PEGylated liposomes containing docetaxel with degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases: a study in CC-531 liver tumor-bearing WAG RIJ rats.
U. Pohlen (2011)
10.1021/bc400326y
Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Nicolas Duhem (2014)
10.1002/9783527634057.CH28
Development of PEGylated Liposomes
I. C. Henderson (2011)
10.1371/journal.pone.0074753
Tocotrienol-Adjuvanted Dendritic Cells Inhibit Tumor Growth and Metastasis: A Murine Model of Breast Cancer
Sitti Rahma Abdul Hafid (2013)
10.1038/s41416-018-0235-2
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
P. Munster (2018)
10.4236/abcr.2020.92003
Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer
S. Khallaf (2020)
10.1016/j.jacc.2014.03.011
Challenges facing early career academic cardiologists.
C. Tong (2014)
10.1007/s00280-014-2378-z
Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old
M. Gusella (2014)
10.1016/j.ejca.2013.04.027
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
C. Falandry (2013)
10.1021/jm201653u
Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate.
B. S. Chhikara (2012)
10.1111/j.2042-7158.2011.01352.x
Methods for co‐culturing tumour and endothelial cells: systems and their applications
Mallory van Moorst (2011)
Landscape phage fusion protein-modified pharmaceutical nanocarriers for targeted and cytoplasmic delivery of chemotherapeutics to breast cancer cells in vitro and in vivo
T. Wang (2012)
10.1186/s12885-016-2385-z
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
K. Miller (2016)
Ключевые слова: липосомы, мицеллы, микроциркуляция в опухоли, лиганды для направленного транс- порта, противоопухолевые препараты.
M. V. Dmitrieva (2012)
Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity.
O. Shevchuk (2012)
10.1517/13543776.2012.661413
5-Fluorouracil derivatives: a patent review
P. Álvarez (2012)
10.1002/wnan.1343
Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
Jasmine Miller-Kleinhenz (2015)
10.1002/jclp.22083
Acute symptoms of posttraumatic stress and dissociative experiences among female israeli civilians exposed to war: the roles of intrapersonal and interpersonal sources of resilience.
A. Besser (2014)
10.1007/s00405-014-3439-y
Association of immunoexpression of the galectins-3 and -7 with histopathological and clinical parameters in oral squamous cell carcinoma in young patients
J. A. Mesquita (2014)
Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization and in vitro anticancer activity CHAPTER IV – SELF-ASSEMBLING DOXORUBICIN-TOCOPHEROL SUCCINATE PRODRUG AS A NEW DRUG DELIVERY SYSTEM: SYNTHESIS, CHARACTERIZATION AND IN VITRO ANTICANCE
Nicolas Duhem (2013)
10.3892/OL.2012.980
Expression pattern of polypeptide N-acetylgalactosaminyltransferase-10 in gastric carcinoma.
Y. Gao (2013)
10.1186/s12905-018-0579-z
Low uptake of cervical cancer screening among HIV positive women in Gondar University referral hospital, Northwest Ethiopia: cross-sectional study design
Abebe Dires Nega (2018)
10.7868/S0026898415040096
[Changes in the number of copies of genetic loci in gastric cancer].
Oleg Ivanovich Kit (2015)
10.1097/CAD.0000000000000037
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
J. Rom (2014)
10.1016/J.JRP.2016.03.002
Bidirectional associations between hope, optimism and social support, and trauma-related symptoms among survivors of terrorism and their spouses
M. Weinberg (2016)
10.4103/2278-0513.149025
Adverse drug reaction profile of pegylated liposomal doxorubicin versus conventional doxorubicin: An observational study
A. G. Dastidar (2015)
10.1517/14656566.2011.540570
Therapeutic management of breast cancer in the elderly
S. Spazzapan (2011)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1002/9781118590638.CH16
Topoisomerase‐Interacting Agents
T. Skácel (2013)
10.1016/S1773-2247(13)50004-9
Magnetic-fluid-loaded liposomes for MR imaging and therapy of cancer
H. Marie (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar